Celcuity's REVTORPYK Wins FDA Approval in PIK3CA Wild-Type Breast Cancer, Launch Set for Late Q3
CELC has more than doubled off its 52-week low of $13.365.
Summary
Celcuity's REVTORPYK received FDA approval for PIK3CA wild-type advanced breast cancer, marking the company's first commercial product. Launch is planned for late Q3 2026, with a supplemental NDA for the mutant population also expected in Q3.
Key Events · Product Development and Regulatory · CELC
-
FDA Approves REVTORPYK
REVTORPYK (gedatolisib) approved for HR+/HER2- PIK3CA wild-type advanced breast cancer, becoming the first pan-PI3K/mTORC1/2 inhibitor to reach the market. In the VIKTORIA-1 trial, the triplet regimen reduced disease progression risk by 76% (HR=0.24) with median PFS of 9.3 months vs. 2.0 months for fulvestrant alone.
-
Commercial Launch in Late Q3 2026
Celcuity plans to launch REVTORPYK commercially in late Q3 2026, targeting a $10B+ U.S. market opportunity. The company has engaged payers covering 90% of U.S. medical benefit lives and deployed a sales force of 88 oncology specialists.
-
Supplemental NDA for Mutant Population Planned
A supplemental NDA for the PIK3CA mutant cohort will be submitted in Q3 2026, based on positive VIKTORIA-1 data. Approval would expand the label to cover 100% of the 2L+ HR+/HER2- advanced breast cancer market.
-
Strong Efficacy and Safety Profile
The REVTORPYK triplet showed a 32% objective response rate and 17.5-month median duration of response. Over 80% of adverse reactions were grade 1/2, with no dose reductions or discontinuations due to hyperglycemia.
Analysis · CELC · Industrial Applications And Services
The FDA approved Celcuity's lead drug REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer, a first-in-class pan-PI3K/mTORC1/2 inhibitor. This transforms Celcuity from a clinical-stage biotech into a commercial company with a drug that showed a 76% reduction in disease progression risk in its pivotal trial. The approval unlocks a $10B+ U.S. market opportunity, with commercial launch planned for late Q3 2026. The company also plans a supplemental NDA in Q3 2026 for the PIK3CA mutant population, which could double the addressable market. This is the single most important event in the company's history.
At the time of this filing, CELC was trading at $106.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.37 to $151.02. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.